We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Spectral Initiates U.S. Pivotal Trial of Toraymyxin™ in Septic Shock


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Spectral Initiates U.S. Pivotal Trial of Toraymyxin™ in Septic Shock"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Spectral Diagnostics Inc., a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, has announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis.

The Cooper Health System, in Camden, New Jersey, which also acts as the coordinating centre for the EUPHRATES trial, has been screening patients using the FDA approved protocol for inclusion and exclusion criteria. After determining the suitability of the protocol, patients have now been enrolled in the trial.

The EUPHRATES (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock) trial is a randomized, double-blinded control trial of standard of care versus standard of care and Toraymyxin™ directed by Spectral's Endotoxin Activity Assay (EAA™), an FDA cleared assay for use in sepsis. This is the first theranostics trial, a combination therapeutic and diagnostic, in the area of sepsis.

"The initiation of our EUPHRATES trial is a major milestone for the Company. This is a step closer to providing U.S. patients the opportunity to access this therapeutic device," said Dr. Paul Walker, President and CEO of Spectral. "In part due to the few therapeutic options available to treat the more than 250,000 patients diagnosed with severe sepsis in the U.S. each year, this disease remains a leading cause of mortality. Toraymyxin™ has been used safely on more than 70,000 patients worldwide and, when guided by our EAA™ diagnostic, has the potential to address this large unmet medical need. We are now qualifying additional sites and, following the upcoming investigators meeting, anticipate that all 15 sites should be active within the next three months."

The EUPHRATES trial is expected to enroll approximately 360 patients at 15 sites throughout the U.S. and will have a primary end point of 28 day mortality.
Advertisement